AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36847952 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA)
Number of subjects: 7392
Study 36847952 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 7392
Study 36847952 — intervention group
Group type: COMPARATOR
Intervention: Non-users of GLP-1RA
Number of subjects: 7392
Study 36847952 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 7392
Study 36847979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-frequency pressure reactivity index (UL-PRx)
Number of subjects: 47
Study 36847979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean UL-PRx and % time with ICP > 20 mmHg
Number of subjects: 47
Study 36847979 — intervention group
Group type: COMPARATOR
Intervention: Secondary decompressive craniectomy
Number of subjects: 47
Study 36847995 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention conducted by pharmacy students, consisting of an initial call and five follow-up calls
Number of subjects: 720
Study 36847995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI intervention)
Number of subjects: 720
Study 36847995 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 720
Study 36848061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 36848061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 36848061 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 0
Study 36848061 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 36848061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT), Mindfulness-based stress reduction (MBSR), Behavior therapy (BT)
Number of subjects: 0
Study 36848113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone (INC group) - 1 application per nostril, once per day for 12 weeks
Number of subjects: 66
Study 36848113 — intervention group
Group type: COMPARATOR
Intervention: 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (control group)
Number of subjects: 66
Study 36848119 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC intervention (practice facilitation, electronic health record decision support, performance feedback)
Number of subjects: 333596
Study 36848119 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC intervention
Number of subjects: 333596
Study 36848129 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out care
Number of subjects: 1000
Study 36848129 — intervention group
Group type: COMPARATOR
Intervention: Opt-in care
Number of subjects: 1000
Study 36848207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile instant messaging (IM) apps for alcohol reduction intervention
Number of subjects: 20
Study 36848226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle behavior changes during the COVID-19 pandemic
Number of subjects: 1609
Study 36848226 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image perception, change in stress level, and gender identity
Number of subjects: 1609
Study 36848226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BMI
Number of subjects: 1609
Study 36848258 — intervention group
Group type: EXPERIMENTAL
Intervention: Second glaucoma drainage device (SGDD)
Number of subjects: 42
Study 36848258 — intervention group
Group type: COMPARATOR
Intervention: Transscleral cyclophotocoagulation (CPC)
Number of subjects: 42
Study 36848258 — intervention group
Group type: EXPERIMENTAL
Intervention: SGDD
Number of subjects: 42
Study 36848258 — intervention group
Group type: COMPARATOR
Intervention: CPC
Number of subjects: 42
Study 36848311 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (administered to 18 patients, 19% of TMP-SMZ group)
Number of subjects: 105
Study 36848311 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids (untreated patients)
Number of subjects: 105
Study 36848311 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ treatment
Number of subjects: 105
Study 36848344 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization of intervertebral discs by Cutibacterium acnes
Number of subjects: 0
Study 36848344 — intervention group
Group type: COMPARATOR
Intervention: Multiomic analyses of LLIVD colonized and non-colonized
Number of subjects: 0
Study 36848432 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to a thrombectomy-capable center during nighttime
Number of subjects: 949
Study 36848432 — intervention group
Group type: COMPARATOR
Intervention: Transfer to the nearest local stroke center during nighttime
Number of subjects: 949
Study 36848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GAGome progression score
Number of subjects: 50
Study 36848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine GAGome progression score
Number of subjects: 50
Study 36848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GAGome progression score
Number of subjects: 50
Study 36848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GAGome progression score (external validation)
Number of subjects: 50
Study 36848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitivity and specificity
Number of subjects: 50
Study 36848614 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose-adjusted prophylaxis (starting dose, 50 IU/kg) in B-LONG study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized interval-adjusted prophylaxis (initially, 100 IU/kg every 10 days) in B-LONG study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand dosing in B-LONG study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 to 60 IU/kg every 7 days in Kids B-LONG study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis (20-100 IU/kg every 7 days) in B-YOND study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis (100 IU/kg every 8-16 days) in B-YOND study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prophylaxis in B-YOND study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand dosing in B-YOND study
Number of subjects: 153
Study 36848635 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rFIXFc prophylaxis
Number of subjects: 153
Study 36848639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan 1080 mg subcutaneously twice weekly for 26 weeks
Number of subjects: 53
Study 36848639 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only (control)
Number of subjects: 53
Study 36848639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 53
Study 36848714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 150
Study 36848714 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT with written accounts (CPT+A)
Number of subjects: 150
Study 36848714 — intervention group
Group type: COMPARATOR
Intervention: Written accounts (WA)
Number of subjects: 150
Study 36848727 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt list and video intervention
Number of subjects: 189
Study 36848727 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study 36848897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation along with oral rehydration solution (ORS)
Number of subjects: 1399
Study 36848897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1399
Study 36848897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 1399
Study 36848918 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 760
Study 36848918 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 760
Study 36848918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 36848919 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 775
Study 36848919 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 775
Study 36848919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study 36848922 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic and bariatric surgery (MBS)
Number of subjects: 50
Study 36848922 — intervention group
Group type: COMPARATOR
Intervention: Intensive non-surgical treatment
Number of subjects: 50
Study 36849009 — intervention group
Group type: EXPERIMENTAL
Intervention: mogroside V and stevia RebM
Number of subjects: 60
Study 36849009 — intervention group
Group type: EXPERIMENTAL
Intervention: stevia RebA and thaumatin
Number of subjects: 60
Study 36849009 — intervention group
Group type: EXPERIMENTAL
Intervention: stevia RebA-thaumatin
Number of subjects: 60
Study 36849009 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralose-ace-K
Number of subjects: 60
Study 36849009 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralose-acesulfame K
Number of subjects: 60
Study 36849009 — intervention group
Group type: COMPARATOR
Intervention: sucrose
Number of subjects: 60
Study 36849097 — intervention group
Group type: EXPERIMENTAL
Intervention: MCDBT-1
Number of subjects: 1693
Study 36849097 — intervention group
Group type: EXPERIMENTAL
Intervention: MCDBT-2
Number of subjects: 1693
Study 36849106 — intervention group
Group type: EXPERIMENTAL
Intervention: Infinity brush
Number of subjects: 51
Study 36849106 — intervention group
Group type: COMPARATOR
Intervention: RX Cytology Brush
Number of subjects: 51
Study 36849161 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-particle curcumin (90 mg/day)
Number of subjects: 533
Study 36849161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 36849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Monitoring Package (AMoPac)
Number of subjects: 7
Study 36849193 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs' acceptance of AMoPac
Number of subjects: 7
Study 36849193 — intervention group
Group type: COMPARATOR
Intervention: Integrated transmission of adherence reports to GPs
Number of subjects: 7
Study 36849205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive triamcinolone acetonide (TA)
Number of subjects: 280
Study 36849205 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 280
Study 36849212 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion (16 pmol/kg/min)
Number of subjects: 60
Study 36849212 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide injections (0.5 mg once-weekly)
Number of subjects: 60
Study 36849212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous)
Number of subjects: 60
Study 36849212 — intervention group
Group type: COMPARATOR
Intervention: Continuous placebo (subcutaneous)
Number of subjects: 60
Study 36849448 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Pennsylvania Smell Identification Test (UPSIT)
Number of subjects: 9396
Study 36849448 — intervention group
Group type: COMPARATOR
Intervention: Self-reported hyposmia
Number of subjects: 9396
Study 36849494 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line osimertinib
Number of subjects: 0
Study 36849516 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 78
Study 36849753 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic major hepatectomy
Number of subjects: 0
Study 36849753 — intervention group
Group type: COMPARATOR
Intervention: Open major hepatectomy
Number of subjects: 0
Study 36849797 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (onabotA) injections
Number of subjects: 10
Study 36849797 — intervention group
Group type: COMPARATOR
Intervention: Pre onabotA
Number of subjects: 10
Study 36849797 — intervention group
Group type: EXPERIMENTAL
Intervention: Active onabotA
Number of subjects: 10
Study 36849838 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (two-dose vaccination)
Number of subjects: 93
Study 36849838 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (two-dose vaccination)
Number of subjects: 93
Study 36849838 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Number of subjects: 93
Study 36849841 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (INT)
Number of subjects: 631
Study 36849955 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide + Cladribine
Number of subjects: 0
Study 36849955 — intervention group
Group type: COMPARATOR
Intervention: Single drug control (either Chidamide or Cladribine)
Number of subjects: 0
Study 36849969 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib 4.5 mg/kg/day
Number of subjects: 358
Study 36849969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 36849969 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib 6.0 mg/kg/day (titrated)
Number of subjects: 358
Study 36849984 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-death experience (NDE) assessment using the Greyson NDE scale (cut-off score ≥ 7/32)
Number of subjects: 126
Study 36849984 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using the EuroQol five-dimensional questionnaire
Number of subjects: 126
Study 36849990 — intervention group
Group type: EXPERIMENTAL
Intervention: Real bihemispheric tDCS (20 min, 2 mA, during task practice twice daily for 20 sessions in two weeks)
Number of subjects: 27
Study 36849990 — intervention group
Group type: COMPARATOR
Intervention: Sham bihemispheric tDCS
Number of subjects: 27
Study 36849996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 68
Study 36849996 — intervention group
Group type: COMPARATOR
Intervention: Control (no HCQ)
Number of subjects: 68
Study 36850012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling immobilization for the first three postoperative weeks
Number of subjects: 68
Study 36850012 — intervention group
Group type: COMPARATOR
Intervention: No sling immobilization
Number of subjects: 68
Study 36850012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling immobilization
Number of subjects: 68
Study 36851177 — intervention group
Group type: EXPERIMENTAL
Intervention: WIV04 vaccine (5μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Number of subjects: 9309
Study 36851177 — intervention group
Group type: EXPERIMENTAL
Intervention: HB02 vaccine (4μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Number of subjects: 9309
Study 36851177 — intervention group
Group type: COMPARATOR
Intervention: Alum-only group (control)
Number of subjects: 9309
Study 36851177 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (WIV04, HB02, alum-only)
Number of subjects: 9309
Study 36851196 — intervention group
Group type: EXPERIMENTAL
Intervention: CV0501 mRNA-based Omicron COVID-19 vaccination (specific dosage and duration not mentioned)
Number of subjects: 0
Study 36851196 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine formulations (specific dosage and duration not mentioned)
Number of subjects: 0
Study 36851204 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg + 5 µg vaccine formulation
Number of subjects: 116
Study 36851204 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg + 20 µg vaccine formulation
Number of subjects: 116
Study 36851204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 36851617 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1C tropism analysis using genotypic tools
Number of subjects: 5602
Study 36851662 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 103
Study 36851662 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine with previous infection
Number of subjects: 103
Study 36851662 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 103
Study 36851662 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 103
Study 36852100 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention group (10 sessions over approximately 5 weeks)
Number of subjects: 366
Study 36852100 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided relaxation intervention group (video sessions ranging from 2 to 20 min each viewed daily over 5 weeks)
Number of subjects: 366
Study 36852100 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (standard clinical care for sickle cell disease)
Number of subjects: 366
Study 36852100 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention group
Number of subjects: 366
Study 36852100 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided relaxation intervention group
Number of subjects: 366
Study 36852100 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 366
Study 36852107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus velpatasvir (SOF/VEL) 400/100 mg once daily for 8 weeks
Number of subjects: 20
Study 36852107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus velpatasvir (SOF/VEL)
Number of subjects: 20
Study 36852452 — intervention group
Group type: EXPERIMENTAL
Intervention: High PD-L1 expression by tumor cells
Number of subjects: 0
Study 36852452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PD-L1 expression
Number of subjects: 0
Study 36852452 — intervention group
Group type: COMPARATOR
Intervention: High PD-L1 levels
Number of subjects: 0
Study 36852670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 0
Study 36852670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36852705 — intervention group
Group type: EXPERIMENTAL
Intervention: Linerixibat 40 mg BID
Number of subjects: 147
Study 36852705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 36852705 — intervention group
Group type: EXPERIMENTAL
Intervention: Linerixibat (various doses)
Number of subjects: 147
Study 36852705 — intervention group
Group type: EXPERIMENTAL
Intervention: Linerixibat
Number of subjects: 147
Study 36852723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab (22.5-750 mg or 10 mg/kg every 2 weeks)
Number of subjects: 507
Study 36852723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab
Number of subjects: 507
Study 36852998 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-HIGIV 100 mg/kg
Number of subjects: 28
Study 36852998 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-HIGIV 200 mg/kg
Number of subjects: 28
Study 36852998 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-HIGIV 400 mg/kg
Number of subjects: 28
Study 36852998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: Prednisone for 14 to 28 days at presentation of IgAV
Number of subjects: 1963
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1963
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 1963
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) cyclophosphamide
Number of subjects: 1963
Study 36853224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 1963
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 1963
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 1963
Study 36853224 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 1963
Study 36853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation
Number of subjects: 224
Study 36853250 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 224
Study 36853388 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR (near-infrared autofluorescence) group
Number of subjects: 147
Study 36853388 — intervention group
Group type: COMPARATOR
Intervention: NONIR (standard care) group
Number of subjects: 147
Study 36853598 — intervention group
Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 72
Study 36853598 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 72
Study 36853598 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery
Number of subjects: 72
Study 36853611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug approach with standard of care (static cold storage)
Number of subjects: 72
Study 36853611 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (control group)
Number of subjects: 72
Study 36853611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug approach
Number of subjects: 72
Study 36853611 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 36853612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (1.5 g), thiamine hydrochloride (100 mg), and hydrocortisone sodium succinate (50 mg) every 6 hours for 96 hours
Number of subjects: 213
Study 36853612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C, thiamine, and hydrocortisone
Number of subjects: 213
Study 36853612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 36853627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation (uRDN)
Number of subjects: 506
Study 36853627 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 506
Study 36853719 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nuclei RNA-Seq
Number of subjects: 0
Study 36853754 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Suicidal Ideation (SI)
Number of subjects: 249
Study 36853754 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe SI
Number of subjects: 249